The company outlined its plans to launch a kidney transplant rejection test that is based on cell-free DNA in 2019 and described its progress in breast cancer research.
The Boston-based startup wants to help individuals interpret their HLA data for ancestry and health, and participate in research studies.
Milwaukee, Wis.-based TAI Diagnostics is developing a PCR-based assay for cell-free DNA as a way to monitor the health of transplanted organs.
Investigators characterized expression activity in kidney grafts from a group of transplant recipients who remained rejection-free without immunosuppression.
The researchers plan to evaluate cfDNA and single cells isolated from the urine of patients who have had kidney transplants to identify signs of graft failure.
Piper Jaffray analyst William Quirk said the pricing, which was much higher than expected, will help push CareDx toward profitability.
The final LCD covers AlloSure in renal allograft recipients who have a probability of active renal allograft rejection.
The software provides analysis of HLA typing by NGS on several platforms, including ones from Illumina, Thermo Fisher, and PacBio.
The company said revenues from its non-invasive heart transplant rejection test AlloMap rose about 16 percent year over year.
The researchers plan to work with the NIH's Genome Research Alliance for Transplantation consortium to compare their method with others.
The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.
Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.
CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.
In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.